Shire acquired FerroKin BioSciences for $100M upfront plus up to $225M in clinical/regulatory/sales milestones. Added Phase 2 oral iron chelator FBS0701 (orphan-designated) to Shire's hematology business.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
AnnouncedMar 15, 2012
ClosedApr 26, 2012
Deal value$325M
Deal typeAcquisition/Merger
Therapeutic areaChronic iron overload from blood transfusions (thalassemia, MDS)
IndicationsChronic iron overload from blood transfusions (thalassemia, MDS)